Sundowning
Imagine a world where the approaching dusk doesn't bring calm, but a surge of confusion, agitation, and restlessness. This unsettling phenomenon, known as sundowning, profoundly impacts individuals with dementia and their caregivers as evening falls. Though still not fully understood, sundowning offers a fascinating glimpse into the delicate balance of our internal clocks and the profound effects of their disruption. Sundowning is a distinct pattern of increased confusion and agitation in dementia patients, typically surfacing in the late afternoon and evening, presenting significant challenges for care. The primary suspected cause of sundowning is a disruption of the body's natural circadian rhythms, influenced by fading light and altered neurochemistry in the aging brain. While treatments are still evolving, a combination of consistent routines, environmental adjustments, and sometimes medication can help manage the challenging symptoms of sundowning.
AI Summary
Imagine a world where the approaching dusk doesn't bring calm, but a surge of confusion, agitation, and restlessness. This unsettling phenomenon, known as sundowning, profoundly impacts individuals with dementia and their caregivers as evening falls. Though still not fully understood, sundowning offers a fascinating glimpse into the delicate balance of our internal clocks and the profound effects of their disruption.
- Sundowning is a distinct pattern of increased confusion and agitation in dementia patients, typically surfacing in the late afternoon and evening, presenting significant challenges for care.
- The primary suspected cause of sundowning is a disruption of the body's natural circadian rhythms, influenced by fading light and altered neurochemistry in the aging brain.
- While treatments are still evolving, a combination of consistent routines, environmental adjustments, and sometimes medication can help manage the challenging symptoms of sundowning.
The Enigma of Sundowning
Sundowning, or sundown syndrome, describes a perplexing pattern observed in people with certain forms of dementia. As the late afternoon arrives and daylight begins to fade, these individuals often experience a marked increase in confusion, restlessness, and even agitation. The term itself was coined in 1987 by nurse Lois K. Evans, perfectly capturing the association between these behaviors and the setting sun.
What It Looks Like
The symptoms of sundowning can be quite varied, but they consistently emerge as natural light diminishes. Patients may appear more disoriented, struggling to recognize familiar faces or places. Shadows can become frightening, contributing to an overall sense of unease and heightened confusion.
Beyond confusion, agitation and mood swings are hallmarks of sundowning. Individuals might become easily frustrated, irritable, or even begin yelling. Physical fatigue often intensifies these emotional states, leading to restlessness, pacing, or even wandering, which can be dangerous for someone in a confused state.
In some cases, the experience can escalate to visual and auditory hallucinations or paranoia. These vivid and unsettling perceptions further increase anxiety, making it incredibly challenging for caregivers to provide comfort or necessary assistance.
More Than Just 'Bad Moods'
It's crucial to distinguish sundowning from delirium, which is an acute, sudden onset of confusion that can occur at any time. Sundowning, by contrast, is a patterned, time-dependent phenomenon. Its predictable timing is key to understanding its underlying mechanisms and managing its impact.
Sundowning is not just a transient annoyance; it has significant adverse outcomes for both those affected and their caregivers. It can lead to longer hospital stays, increased financial burdens, and a steeper decline in cognitive function. For caregivers, the relentless nature of these evening behaviors often results in heightened stress and burnout.
Research indicates that between 20-45% of people with Alzheimer's disease experience some form of sundowning. It most commonly occurs during the middle stages of the disease, often subsiding as the dementia progresses to its later phases, suggesting a complex neurological dance.
Unraveling the Causes
While the exact mechanisms behind sundowning are not fully proven, the leading theory points to a disruption in our body's finely tuned internal clock—the circadian rhythm. This natural cycle regulates sleep-wake patterns, hormone release, and many other physiological processes over a 24-hour period.
Normally, as the sun sets, our bodies initiate a biochemical cascade, preparing us for sleep. Dopamine levels decrease, and the pineal gland ramps up production of melatonin, the 'sleep hormone.' For individuals with dementia, this delicate balance can be thrown off-kilter, with decreased melatonin production potentially disrupting other vital neurotransmitter systems.
The Alzheimer's Connection
In Alzheimer's disease, the accumulation of amyloid plaques and neurofibrillary tangles is thought to disrupt the suprachiasmatic nucleus (SCN). Located in the hypothalamus, the SCN is our body's master clock, intensely sensitive to external light and dark cues. Damage here could directly impair the regulation of sleep patterns and circadian rhythms, explaining the confusion seen in sundowning.
Serotonin, a neurotransmitter known for its role in mood, aggression, and circadian rhythm, also appears to be involved. Deficiencies in serotonin signaling, common in Alzheimer's, could exacerbate circadian disruption and increase agitation, connecting multiple threads of this complex syndrome.
Other Contributing Factors
Beyond core neurological changes, several other factors can contribute to or worsen sundowning. These include hormonal fluctuations, disturbances in REM sleep, and general fatigue in both the individual with dementia and their caregiver. Even environmental cues, like reduced staff presence and increased noise in institutional settings during the evening, can act as triggers.
Who is at Risk?
Sundowning isn't exclusive to Alzheimer's. It's often associated with a range of neurological disorders like Parkinson's, Huntington's, and Lewy body dementia. Neurobehavioral conditions such as anxiety and depression also increase vulnerability, as do cerebrovascular disease risk factors like hypertension and obesity. Genetic predispositions, such as the ApoE4 allele, further raise the risk.
Navigating Treatment and Care
Given the complex nature of sundowning, clinical trials guiding treatment remain limited. Current approaches often involve a combination of non-pharmacological strategies to create a supportive environment and, in some cases, targeted medications.
Non-Pharmacological Approaches
Establishing a consistent daily routine and sleep schedule is paramount. Promoting increased physical activity during the day and limiting naps and caffeine, especially in the afternoon, can help consolidate nighttime sleep. Even simple measures like allowing the person to choose their preferred sleeping spot or providing a dim nightlight can reduce confusion and anxiety.
Environmental adjustments play a huge role. Reducing overwhelming noise in the late afternoon can ease the transition to evening. Light therapy, exposing individuals to bright light during the day, aims to help reset their circadian rhythms, though evidence is still developing. Softer approaches like music therapy or aromatherapy are also explored, focusing on comfort and relaxation.
Pharmacological Interventions
Melatonin, a natural hormone, is often used to help induce sleep and regulate sleep-wake cycles, showing some promise in regularizing sleep patterns and even improving mood and memory in some Alzheimer's patients. Its effectiveness supports the theory of circadian disruption.
Other drug classes, including hypnotics, benzodiazepines, and certain antipsychotics, have been used to manage severe agitation. However, these come with significant side effects like increased fall risk, vivid dreams, or even paradoxical nocturnal agitation, necessitating a careful risk-benefit assessment for each individual.
The Frontier of Research
Scientists are actively exploring several promising avenues for therapeutic options. Research into enzymes like NADH cytochrome C reductase and thioredoxin reductase aims to understand and counter the oxidative stress and neuron damage that might contribute to neurodegeneration and SCN impairment.
Investigating inflammatory stress and its relationship with cytokines like IL-1β could shed light on how inflammation contributes to neurodegeneration. Perhaps the most futuristic approach involves chemogenetics—injecting ligands into the eye to directly stimulate the SCN via the retinohypothalamic tract, potentially offering a novel way to reset the body's clock.
Acknowledging the Controversy
Despite its significant impact, sundown syndrome isn't officially recognized as a distinct diagnosis in the DSM-5, the Diagnostic and Statistical Manual of Mental Disorders. This lack of official classification sometimes sparks debate, with some questioning whether it's a distinct syndrome or simply caregivers' perception of increased agitation at a specific time of day.
Adding to the complexity, some studies have noted sundowning-like behaviors occurring at times other than actual sunset, suggesting that the symptoms might be more broadly time-dependent rather than strictly linked to the fading light. This ongoing discussion highlights the need for continued, robust research to fully understand this challenging and common phenomenon.
Article
Sundowning
Sundowning, or sundown syndrome, prevalent among people with some form of dementia, is characterized by increased confusion and restlessness beginning in the late afternoon and early evening. The term sundowning was coined by nurse Lois K. Evans in 1987 due to the association between the person's increased confusion and the setting of the sun.
For people with sundown syndrome, a multitude of behavioral problems begin to occur and are associated with long-term adverse outcomes. Sundowning seems to occur more frequently during the middle stages of Alzheimer's disease and mixed dementia and seems to subside with the progression of the person's dementia. People are generally able to understand that this behavioral pattern is abnormal. Research shows that 20–45% of people with Alzheimer's will experience some variation of sundowning confusion. However, despite lack of an official diagnosis of sundown syndrome in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), there is currently a wide range of reported prevalence.
Relevance
Sundowning
The following social, economic, and physiological adverse outcomes are correlated with individuals affected by sundowning and their caregivers:
• Long-term admission to psychiatric care facilities. • Prolonged hospital admission with recurrent visits that increase financial burden. • Steeper cognitive decline in Alzheimer's disease. • Decreased quality of life. • Increased stress and burnout of caregivers due to the timing of sundowning symptom onset.
Symptoms
Sundowning
• Increased general confusion as natural light begins to fade and increased shadows appear. • Agitation and mood swings. Individuals may become fairly frustrated with their own confusion as well as aggravated by noise. Individuals being found yelling and becoming increasingly upset with their caregivers are not uncommon. • Mental and physical fatigue increase with the setting of the sun. This fatigue can play a role in the individual's irritability. • An individual may experience an increase in restlessness while trying to sleep. Restlessness can often lead to pacing and or wandering which can be potentially harmful for an individual in a confused state. • Hallucinations (visual and auditory) and paranoia can cause increased anxiety and resistance to care.
Causes
Sundowning
While the specific causes of sundowning have not been empirically proven, some evidence suggests that circadian rhythm disruption increases sundowning behaviors. In humans, sunset triggers a biochemical cascade that involves a reduction of dopamine levels and a shift towards melatonin production as the body prepares for sleep. In individuals with dementia, melatonin production may be decreased, which may interrupt other neurotransmitter systems.
Other causes or precipitating factors that may lead to sundown syndrome may include hormonal changes, disturbances in REM sleep, individual and/or caregiver fatigue, inappropriate medication use, or being predisposed to behavioral disorders from chronic neurological diseases. Resources in an institution's environment can also play a role as a symptom trigger. A reduced number of staff in the evening can be attributed to more unmet needs and a lower threshold for agitation for individuals with sundown syndrome.
Sundowning should be distinguished from delirium, and could be presumed to be delirium when it appears as a new behavioral pattern until a causal link between sunset and behavioral disturbance is established. People with established sundowning and no obvious medical illness may be suffering from impaired circadian regulation, or may be affected by nocturnal aspects of their institutional environment such as shift changes, increased noise, or reduced staffing (which leads to fewer opportunities for social interaction). Delirium is generally an acute event that can span hours to days.
Connection to Alzheimer's disease
It is thought that with the development of plaques and tangles associated with Alzheimer's disease there might be a disruption within the suprachiasmatic nucleus (SCN). The SCN is located in the hypothalamus and is associated with regulating sleep patterns by maintaining circadian rhythms, which are strongly associated with external light and dark cues. A disruption within the suprachiasmatic nucleus would seem to be an area that could cause the types of confusion that are seen in sundowning. However, finding evidence for this is difficult, as an autopsy is needed to analyze this disruption properly. By the time a person experiencing Alzheimer's has died, they have usually surpassed the level of brain damage (and associated dementia) that would be associated with sundowning. This hypothesis is, however, supported by the effectiveness of melatonin, a natural hormone, to decrease behavioral symptoms associated with sundowning. The pineal gland produces melatonin when signaled by the SCN to help maintain circadian rhythms. Melatonin supplementation can be administered to older adults as their natural hormonal production decreases over time.
Serotonin has also been observed to potentially have a key role in the regulation of circadian rhythm as research has shown that serotonergic agonism in the SCN results in "phase shifts" in portions of the light-dark cycle. In addition to the effects on circadian rhythm, serotonin is also known to be involved in the regulation of aggression. Due to the serotonergic signaling deficiencies of Alzheimer's disease, it has been commonly reported that deficiencies in serotonin have been associated with worsening circadian rhythm or aggression.
Risk factors
Elderly people often experience multiple comorbidities that may contribute to the phenomenon of sundowning syndrome through neurodegeneration.
• Neurological disorders: Alzheimer's disease, Parkinson's disease, Huntington's disease, Lewy body dementia, fronto-temporal dementia, subcortical dementia. • Neurobehavioral disorders: anxiety and depression. • Cerebrovascular disease risk factors: hypertension, smoking, obesity. • Genetic predisposition: presence of the ApoE4 allele has associations with sundown syndrome in people experiencing Alzheimer's disease.
Treatment
Sundowning
Scant clinical trials exist to guide treatment. Current treatment proposals have limited justifications for their use. Treatment of sundown syndrome may vary based on when agitated behavior is observed throughout the day.
Non-pharmacological treatments
• If possible, a consistent sleeping schedule and daily routine that a patient is comfortable with can reduce confusion and agitation. • If the person's condition permits, having increased daily activity incorporated into their schedule can help promote an earlier bedtime and need for sleep. • Check for over-napping. People may wish to take naps during the day, but unintentionally getting too much sleep will affect nighttime sleep. Physical activity is a treatment for Alzheimer's and a way to encourage night sleep. • Caffeine is a (fast-working) brain stimulant, but should be limited at night if a night's sleep is needed. • Caregivers may try letting people choose their own sleeping arrangements each night, wherever they feel most comfortable sleeping, as well as allow for a dim light in the room to alleviate confusion associated with an unfamiliar place. • Light therapy can help regulate circadian rhythms. Older adults can struggle to receive consistent sunlight due to bedrest and institutional limitations. Mood and spatial positioning improvements have been noted in people experiencing dementia with exposure to indoor light, but the evidence is currently inconclusive. • Reducing the amount of overwhelming noise in the late afternoon or early evening can help the transition to sleep. • Music therapy, aromatherapy, acupressure, psychosocial support, caregiver education, multi-sensory stimulation, and simulated presence therapy are possible treatment pathways, but evidence is currently lacking in clinical practice. • Exercising at consistent times daily has been proposed to improve circadian rhythm and reduce the symptoms of sundown syndrome in people with Alzheimer's and dementia. It has also been observed that people with Alzheimer's walking in the morning or afternoon had improvements in sundowning symptoms.
Pharmacological treatments
• Some evidence supports the use of melatonin to induce sleep. The length of time required for a person to transition from fully awake to asleep has been shown to be more regular in melatonin users. Better memory and more positive emotional states have also been observed in people experiencing Alzheimer's disease. • Drug classes such as hypnotics, benzodiazepines, acetylcholinesterase inhibitors (AChIs), N-methyl D-aspartic acid antagonists (NMDA), selective serotonin reuptake inhibitors (SSRIs), and sedative antipsychotics have been used to treat sundowning, but their side effects limit their overall effectiveness in a risk versus benefit balance. Various side effects in the risk category include increased fall risk, vivid dreams, or nocturnal agitation.
Research directions
Sundowning
There are several pathways in the pipeline for scientists seeking therapeutic options for sundowning syndrome.
• NADH cytochrome C reductase is an enzyme involved in the synthesis of neuron energy. Stress, hypometabolism, and oxidative damage may decrease physiologic reserve in the elderly and can lead to a decrease in neuron energy production and an increase in neuron damage. • Thioredoxin reductase is an antioxidant that neutralizes oxidative free radicals that can cause cell death. The brain is vulnerable to oxidative free radicals because it receives 20% of the human body's oxygen supply. Finding a way to maintain the thioredoxin reductase pathway can decrease plaque formation and SCN degeneration. • Inflammatory stress in mouse models can provide a pathway for studying neurodegeneration. It is hypothesized that neurodegeneration has a relationship with inflammatory cytokines such as IL-1β. The role of cytokines in sundowning can improve our understanding of the pathology. • Injection of chemogenetic ligands into the eye to stimulate the SCN through the retinohypothalamic tract is another possible treatment for sundown syndrome as a similar strategy has been thought to have potential with regards to therapy for mood-related disorders.
Controversy
Sundowning
In addition to sundown syndrome not being officially recognized in the DSM-5, there is also the thought that sundown syndrome may be a phenomenon of caretakers' perception of patient agitation in the early afternoon to evening. Some studies have observed sundown syndrome occurring at times other than sunset which may suggest the symptoms associated with sundown syndrome are time-dependent rather than occurring specifically at sundown.